103 related articles for article (PubMed ID: 26734784)
1. 'Tablet burden' in patients with metastatic breast cancer.
Milic M; Foster A; Rihawi K; Anthoney A; Twelves C
Eur J Cancer; 2016 Mar; 55():1-6. PubMed ID: 26734784
[TBL] [Abstract][Full Text] [Related]
2. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer.
Fallowfield L; Atkins L; Catt S; Cox A; Coxon C; Langridge C; Morris R; Price M
Ann Oncol; 2006 Feb; 17(2):205-10. PubMed ID: 16239231
[TBL] [Abstract][Full Text] [Related]
3. Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer.
Calip GS; Xing S; Jun DH; Lee WJ; Hoskins KF; Ko NY
J Oncol Pract; 2017 May; 13(5):e451-e462. PubMed ID: 28287854
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
5. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
Ciruelos EM; Díaz MN; Isla MD; López R; Bernabé R; González E; Cirauqui B; Coves J; Morales S; Arcediano A; Barneto I; Cerezuela P; Illarramendi JJ; Morales C; Ponce S
Eur J Cancer Care (Engl); 2019 Nov; 28(6):e13164. PubMed ID: 31571304
[TBL] [Abstract][Full Text] [Related]
6. The preferences and experiences of different bisphosphonate treatments in women with breast cancer.
Fallowfield L; Stebbing J; Braybrooke J; Langridge C; Jenkins V
Psychooncology; 2011 Jul; 20(7):755-61. PubMed ID: 20878871
[TBL] [Abstract][Full Text] [Related]
7. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
9. [Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions].
Morimoto K; Taguchi T; Ohta J; Miura S; Ueda N; Yayoi K; Inaji H
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1041-8. PubMed ID: 1385688
[TBL] [Abstract][Full Text] [Related]
10. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
11. What non-prescription treatments do UK women with breast cancer use?
Catt S; Fallowfield L; Langridge C
Eur J Cancer Care (Engl); 2006 Jul; 15(3):279-85. PubMed ID: 16882125
[TBL] [Abstract][Full Text] [Related]
12. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
13. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
Gupta S; Zhang J; Jerusalem G
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198
[TBL] [Abstract][Full Text] [Related]
14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
15. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
16. Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer.
Jacobs JM; Pensak NA; Sporn NJ; MacDonald JJ; Lennes IT; Safren SA; Pirl WF; Temel JS; Greer JA
J Oncol Pract; 2017 May; 13(5):e474-e485. PubMed ID: 28398843
[TBL] [Abstract][Full Text] [Related]
17. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
[TBL] [Abstract][Full Text] [Related]
18. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer.
Ogawa Y; Ishikawa T; Chung SH; Ikeda K; Takashima T; Onoda N; Nakata B; Nishiguchi Y; Hirakawa K
Anticancer Res; 2003; 23(4):3453-7. PubMed ID: 12926089
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
20. An Analysis of Medication Adherence and Patient Preference in Long-term Stable Maintenance Hemodialysis Patients in Japan.
Ohya M; Iwashita Y; Kunimoto S; Yamamoto S; Mima T; Negi S; Shigematsu T
Intern Med; 2019 Sep; 58(18):2595-2603. PubMed ID: 31178499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
